PTX-100
Relapsed/refractory Cutaneous T‑Cell Lymphoma
Phase 2aActive
Key Facts
Indication
Relapsed/refractory Cutaneous T‑Cell Lymphoma
Phase
Phase 2a
Status
Active
Company
About Prescient Therapeutics
Australian early‑stage oncology biotech leveraging a GGT‑1 inhibitor and novel CAR‑T platforms to address unmet‑need cancers.
View full company profile